https://www.pharmaradar360.com/article/bc0a96684d6a00a5PharmaRadar360en2026-04-03T01:00:00.000ZMenicon Renames Its Sales Subsidiaries in Malaysia and Indonesia – Promoting Brand Integration and Business Expansion in Southeast Asia –https://www.pharmaradar360.com/article/f0a809b2df1cd379PharmaRadar360en2026-04-03T00:00:00.000ZBristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026https://www.pharmaradar360.com/article/721ba76c6198b4a6PharmaRadar360en2026-04-03T00:00:00.000ZBazar el Regalo raises €13,644 for personalised medicine and paediatric cancer researchhttps://www.pharmaradar360.com/article/9e969e73c1339af9PharmaRadar360en2026-04-02T16:00:00.000ZLa FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o aguahttps://www.pharmaradar360.com/article/4387a8639a1018acPharmaRadar360en2026-04-02T12:30:00.000ZAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New Yorkhttps://www.pharmaradar360.com/article/4ee85ecdd20d96d3PharmaRadar360en2026-04-02T12:00:00.000ZEmergent BioSolutions Participates in Upcoming International Preparedness Conferenceshttps://www.pharmaradar360.com/article/904dabca01527d35PharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancerhttps://www.pharmaradar360.com/article/0676c51a13496ff4PharmaRadar360en2026-04-02T10:00:00.000ZReply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial," and "Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer"https://www.pharmaradar360.com/article/e4c6eef3c3da33d0PharmaRadar360en2026-04-02T10:00:00.000ZKey Methodological Considerations in the Interpretation of the CONKO-007 Trialhttps://www.pharmaradar360.com/article/950421846a24d0cePharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy in Pancreatic Cancer: Toward Precision Oncologyhttps://www.pharmaradar360.com/article/aaa1659b71b8c860PharmaRadar360en2026-04-02T10:00:00.000ZGonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trialhttps://www.pharmaradar360.com/article/0200ca85867ba791PharmaRadar360en2026-04-02T10:00:00.000ZBreaking new ground with antibody-drug conjugates in myelomahttps://www.pharmaradar360.com/article/261e01272bcbad88PharmaRadar360en2026-04-02T10:00:00.000ZAccess to CAR T-cell therapy across diverse global marketshttps://www.pharmaradar360.com/article/d36dbe98ec8d7314PharmaRadar360en2026-04-02T10:00:00.000ZFan X, Xi Q. Flow cytometry-based evaluation of TRBC1/TRBC2 facilitates identification of indolent T-lymphoblastic proliferations. Blood. 2026;147(6):702https://www.pharmaradar360.com/article/dfe172ba5e8a391bPharmaRadar360en2026-04-02T10:00:00.000ZArora J, Ayyappan S, Yin C, et al. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC. Blood. 2024;143(18):1816-1824https://www.pharmaradar360.com/article/0183d58f5013d66cPharmaRadar360en2026-04-02T10:00:00.000ZMetamizole-induced agranulocytosis resulting in ecthyma gangrenosum after an AI chatbot queryhttps://www.pharmaradar360.com/article/81c1b04b5cbfa7adPharmaRadar360en2026-04-02T08:24:42.000ZThe tumor microbiota: a new frontier in cancer biologyhttps://www.pharmaradar360.com/article/025cba2fbc2e1564PharmaRadar360en2026-04-02T07:30:00.000ZAnnounced: the fifteen shortlisted images in the IDIBAPS 2026 Scientific Photography Competitionhttps://www.pharmaradar360.com/article/60f4996fc166dba8PharmaRadar360en2026-04-02T00:30:00.000ZImfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trialhttps://www.pharmaradar360.com/article/ff7fb19b92f48eefPharmaRadar360en2026-04-02T00:00:00.000ZMultimodal AI model for early detection of hepatocellular carcinomahttps://www.pharmaradar360.com/article/4a6f0c4886066ebdPharmaRadar360en2026-04-02T00:00:00.000Zbio statement section 232 pharmaceutical proclamationhttps://www.pharmaradar360.com/article/6611b9d9dd083178PharmaRadar360en2026-04-02T00:00:00.000ZShionogi Completes Acquisition of All Rights to RADICAVA (edaravone)https://www.pharmaradar360.com/article/db10efb2dc243785PharmaRadar360en2026-04-02T00:00:00.000ZRegeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutionshttps://www.pharmaradar360.com/article/5901f138fbfe590cPharmaRadar360en2026-04-02T00:00:00.000ZEYLEA HD®(aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)https://www.pharmaradar360.com/article/542a94252f3d7ed1PharmaRadar360en2026-04-02T00:00:00.000ZNews 02 April 2026The UK should seek to be a European leader for rare disease medicine, says new reportRead Morehttps://www.pharmaradar360.com/article/be9de79ff3d327abPharmaRadar360en2026-04-02T00:00:00.000Zmaximizing efficiency for our clientshttps://www.pharmaradar360.com/article/a61a205060c4c71fPharmaRadar360en2026-04-02T00:00:00.000Zthe qp in the euhttps://www.pharmaradar360.com/article/1e4608e9f6a54733PharmaRadar360en2026-04-02T00:00:00.000Zwhy it's never too early to start considering clinical supplies as part of your development programhttps://www.pharmaradar360.com/article/c1043634d11529c8PharmaRadar360en2026-04-02T00:00:00.000Ztechnical writing in the pharmaceutical industryhttps://www.pharmaradar360.com/article/0611fee95d67425fPharmaRadar360en2026-04-02T00:00:00.000Zdrug delivery methods and therapies for cancer treatmenthttps://www.pharmaradar360.com/article/8721fab9703ea8c0PharmaRadar360en2026-04-02T00:00:00.000Zpmp exposure to global project management methodologyhttps://www.pharmaradar360.com/article/e290dfac3443583cPharmaRadar360en2026-04-02T00:00:00.000Zpayload linker engineering differentiator adc development manufacturinghttps://www.pharmaradar360.com/article/ea09dc6e72d67c66PharmaRadar360en2026-04-02T00:00:00.000Zwhy choosing the right drug substance cdmo mattershttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-02T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/2ce61ff7c45be5dcPharmaRadar360en2026-04-02T00:00:00.000ZLilly’s Announcement Regarding Oral GLP-1 Foundayo™ (Orforglipron)https://www.pharmaradar360.com/article/7b89c7aaabff18c4PharmaRadar360en2026-04-02T00:00:00.000ZPharming Group announces the filing of its 2025 Annual Report and Form 20-FFinancial updatesApril 2 2026Pharming Group N.V. today announced the filing of its Annual Report for the year ended December 31, 2025.Read morehttps://www.pharmaradar360.com/article/be953d3ba5bcee4dPharmaRadar360en2026-04-02T00:00:00.000ZPositive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy